Nantahala Capital Management LLC Buys New Position in Lexeo Therapeutics, Inc. $LXEO

Nantahala Capital Management LLC purchased a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,300,000 shares of the company’s stock, valued at approximately $6,051,500.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. purchased a new position in Lexeo Therapeutics during the 2nd quarter worth $26,717,000. Affinity Asset Advisors LLC grew its stake in shares of Lexeo Therapeutics by 57.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after acquiring an additional 1,850,211 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $49,650,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $47,299,000. Finally, Vestal Point Capital LP lifted its position in shares of Lexeo Therapeutics by 37.7% during the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock valued at $44,437,000 after purchasing an additional 1,225,000 shares in the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Down 2.6%

LXEO opened at $4.86 on Friday. The stock has a market cap of $398.76 million, a price-to-earnings ratio of -4.23 and a beta of 1.46. Lexeo Therapeutics, Inc. has a twelve month low of $3.99 and a twelve month high of $10.99. The company’s 50-day moving average price is $4.74 and its two-hundred day moving average price is $5.46.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). As a group, sell-side analysts anticipate that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Analysts Set New Price Targets

LXEO has been the topic of several recent analyst reports. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. reduced their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, Wall Street Zen lowered Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $18.75.

Insider Activity at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the transaction, the insider directly owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This represents a 21.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the sale, the chief executive officer directly owned 377,817 shares of the company’s stock, valued at $1,692,620.16. This represents a 6.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 66,326 shares of company stock worth $299,817. 2.00% of the stock is owned by company insiders.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.